Status:
COMPLETED
A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis B, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study is a long-term post-treatment follow-up to study WV19432, which evaluated the efficacy and safety of PEGASYS in patients with HBeAg positive chronic hepatitis B (CHB).Patients who received ...
Eligibility Criteria
Inclusion
- Informed consent for Study WV19432
- Patients who have completed treatment and follow-up on study WV19432
Exclusion
- As for Study WV19432
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
383 Patients enrolled
Trial Details
Trial ID
NCT00927082
Start Date
April 1 2009
End Date
November 1 2014
Last Update
March 9 2016
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Fitzroy, Victoria, Australia, 3065
2
Salvador, Estado de Bahia, Brazil, 40210-341
3
Campinas, São Paulo, Brazil, 13083-888
4
Ribeirão Preto, São Paulo, Brazil, 14049-900